What's new

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised

Mar 17, 2025 - 15:42
 0
Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised
Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 17, Status: Authorised
Read More

Tags:

Previous Article

These Are The Used Cars You Would Buy With $10,000

Next Article

FERC reaffirms approval of Southeastern SEEM market

Related Posts

Orphan designation: (R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)pyrrolidin-1-yl)(5-hydroxy-6-methylpyridin-2-yl)methanone Treatment of Olmsted syndrome, 26/02/2025 Positive

Orphan designation: (R)-(3-(2'-cyclopropyl-3-(hydr...

Mar 11, 2025  0

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

Webinar on PMS Project Made Easy: Summary of activities and Practical Tips for SMEs, Online, European Medicines Agency, Amsterdam, the Netherlands, from 24 February 2025, 14:00 (CET) to 24 February 2025, 16:00 (CET)

Webinar on PMS Project Made Easy: Summary of activities...

Feb 11, 2025  0